drugset / Trial / NCT03410615

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

NCT03410615 ↗

Phase 2 Active not recruiting 129 enrolled Canadian Cancer Trials Group AstraZeneca · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

Timeline

Start
2018-05-28
Primary completion
2026-01-09
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 100 mg/m2 Intravenous
Subject Durvalumab Monoclonal antibody 1500 mg Intravenous
Subject Tremelimumab Monoclonal antibody — —